Oncopeptides AB (publ) (ONPPF)
USD 0.27
(-70.56%)
USD 0.27
(-70.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -66.92 Million SEK | 80.02% |
| 2022 | -334.97 Million SEK | 3.74% |
| 2021 | -347.99 Million SEK | 57.61% |
| 2020 | -820.9 Million SEK | 10.73% |
| 2019 | -919.53 Million SEK | -144.81% |
| 2018 | -375.61 Million SEK | 7.04% |
| 2017 | -404.05 Million SEK | -903.83% |
| 2016 | -40.25 Million SEK | -1655.38% |
| 2015 | -2.29 Million SEK | 80.84% |
| 2014 | -11.96 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.82 Million SEK | 113.18% |
| 2024 Q2 | -268.38 Million SEK | -3142.95% |
| 2023 Q1 | -171.95 Million SEK | 48.66% |
| 2023 Q2 | -53.93 Million SEK | 68.64% |
| 2023 FY | -66.92 Million SEK | 80.02% |
| 2023 Q3 | -53.16 Million SEK | 1.43% |
| 2023 Q4 | -66.92 Million SEK | -25.88% |
| 2022 Q2 | -84.32 Million SEK | 55.14% |
| 2022 Q3 | -421.5 Million SEK | -399.83% |
| 2022 Q4 | -334.97 Million SEK | 20.53% |
| 2022 FY | -334.97 Million SEK | 3.74% |
| 2022 Q1 | -187.96 Million SEK | 45.99% |
| 2021 Q1 | -368.88 Million SEK | 55.06% |
| 2021 Q2 | -998.11 Million SEK | -170.58% |
| 2021 Q3 | -671.07 Million SEK | 32.77% |
| 2021 Q4 | -347.99 Million SEK | 48.14% |
| 2021 FY | -347.99 Million SEK | 57.61% |
| 2020 Q2 | -924.99 Million SEK | -52.52% |
| 2020 Q1 | -606.46 Million SEK | 34.05% |
| 2020 FY | -820.9 Million SEK | 10.73% |
| 2020 Q4 | -820.9 Million SEK | 33.89% |
| 2020 Q3 | -1.24 Billion SEK | -34.24% |
| 2019 Q2 | -622.69 Million SEK | 16.12% |
| 2019 FY | -919.53 Million SEK | -144.81% |
| 2019 Q1 | -742.38 Million SEK | -97.65% |
| 2019 Q3 | -1.11 Billion SEK | -79.73% |
| 2019 Q4 | -919.53 Million SEK | 17.84% |
| 2018 Q2 | -568.21 Million SEK | 14.55% |
| 2018 Q4 | -375.61 Million SEK | 23.17% |
| 2018 FY | -375.61 Million SEK | 7.04% |
| 2018 Q1 | -664.94 Million SEK | -64.57% |
| 2018 Q3 | -488.86 Million SEK | 13.96% |
| 2017 Q3 | -442.96 Million SEK | 17.21% |
| 2017 Q2 | -535.06 Million SEK | 12.51% |
| 2017 Q4 | -404.05 Million SEK | 8.78% |
| 2017 Q1 | -611.59 Million SEK | -1419.47% |
| 2017 FY | -404.05 Million SEK | -903.83% |
| 2016 Q4 | -40.25 Million SEK | 0.0% |
| 2016 Q1 | 2.29 Million SEK | 0.0% |
| 2016 FY | -40.25 Million SEK | -1655.38% |
| 2015 FY | -2.29 Million SEK | 80.84% |
| 2014 FY | -11.96 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.27 Million USD | 430.045% |
| Skye Bioscience, Inc. | -5.72 Million USD | -1069.646% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -961.46% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -26708.749% |
| Qrons Inc. | 351.42 Thousand USD | 19142.362% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -327810.623% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 1284.767% |
| BioStem Technologies, Inc. | 4.47 Million USD | 1596.419% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 10635.812% |
| CSL Limited | 10.52 Billion USD | 100.636% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 254.073% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 256.381% |
| Rebus Holdings, Inc. | 305 Thousand USD | 22040.984% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -5108296.947% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 10852.55% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 336939.986% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 524.538% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 1725.051% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 16753.021% |
| SQZ Biotechnologies Company | -36.23 Million USD | -84.668% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 3084.525% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 7317.538% |
| Mesoblast Limited | 55.85 Million USD | 219.803% |
| Marizyme, Inc. | 18.56 Million USD | 460.385% |
| Genus plc | 190.6 Million USD | 135.11% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 3093.069% |
| Pharming Group N.V. | 109.8 Million USD | 160.945% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 7879.215% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 5612.864% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 9941.176% |
| ContraFect Corporation | -6.02 Million USD | -1010.521% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 49803.281% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 5891.788% |
| IMV Inc. | 7.67 Million USD | 972.431% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 1316.308% |
| MultiCell Technologies, Inc. | 90.04 USD | 74322623.323% |
| ONE Bio Corp. | 9.04 Million USD | 840.263% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -9017.439% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 616.916% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 4991.917% |
| Q BioMed Inc. | 4.06 Million USD | 1748.273% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 319.022% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 6740.76% |
| Biomind Labs Inc. | 711.4 Thousand USD | 9506.777% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 210.528% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 3447.017% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 622.543% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 18703.875% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 47967.014% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 3139.082% |
| GB Sciences, Inc. | 1.74 Million USD | 3929.874% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -36311.518% |
| HST Global, Inc. | 96.79 Thousand USD | 69237.231% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 32551.253% |
| Halberd Corporation | 144.72 Thousand USD | 46340.698% |
| Enzolytics Inc. | 981.65 Thousand USD | 6917.052% |
| Agentix Corp. | 37.63 Thousand USD | 177932.107% |
| Resverlogix Corp. | 6.45 Million USD | 1137.359% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -9842.222% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 96.702% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -42.347% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 1046.405% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 2570.635% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -657.021% |
| AVAX Technologies, Inc. | -5.9 Million USD | -1033.621% |
| Zenith Capital Corp. | 10.06 Thousand USD | 665044.356% |
| Genscript Biotech Corporation | -1.06 Billion USD | 93.695% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 33487.882% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 2904.654% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 40778.625% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -365223.725% |
| Kadimastem Ltd | -253.1 Thousand USD | -26339.933% |
| Helix BioMedix, Inc. | -2.57 Million USD | -2503.859% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 33351.513% |
| LadRx Corporation | -2.03 Million USD | -3186.08% |
| Cell Source, Inc. | 9.23 Million USD | 824.872% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 10635.812% |
| NovAccess Global Inc. | 2.17 Million USD | 3171.888% |
| Affymax, Inc. | -5.59 Million USD | -1095.641% |
| Itoco Inc. | 228.3 Thousand USD | 29411.666% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 49309.863% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 1450.01% |
| Mobile Lads Corp. | 484.23 Thousand USD | 13919.822% |
| CytoDyn Inc. | 20.26 Million USD | 430.273% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -10343022.102% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -721927.893% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 968.414% |
| SYBLEU INC | 473.71 Thousand USD | 14226.667% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 1601.451% |
| International Stem Cell Corporation | 2.59 Million USD | 2683.784% |
| Bioxytran, Inc. | 1.89 Million USD | 3624.12% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 107321.252% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 3168.458% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 2048.748% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 882.416% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 8761.583% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -5253.6% |
| Neutra Corp. | 52.18 Thousand USD | 128331.169% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -2588.63% |
| PureTech Health plc | -167.19 Million USD | 59.975% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -27224.546% |
| IXICO plc | -4.44 Million USD | -1405.652% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 606.241% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 222.003% |
| CSL Limited | 10.52 Billion USD | 100.636% |
| Cellectis S.A. | -43.81 Million USD | -52.72% |